Some synthetic small molecule compounds have been shown to mechanistically target the PI3K/Akt/mTOR and associated RAS/RAF/MEK/ERK or MAPK signaling pathway as promising treatments against metastatic melanoma [63]. The gene discussed is AKT1; the disease is metastatic melanoma.